Zhuang Luo1, Rongrong Wu2, Yifeng Jiang3, Zhixing Qiu4, Wei Chen5, Weimin Li4. 1. Department of Respiratory Medicine, West China Hospital, Sichuan University Chengdu 610041, Sichuan, PR China ; Department of Respiratory Medicine, The First Affiliated Hospital of Kunming Medical University Kunming 650032, Yunnan, PR China. 2. Department of Radiology, The First People's Hospital of Yunnan Province Affiliated to Kunming University of Science and Technology Kunming 650032, Yunnan, PR China. 3. Department of General Surgery, The Seventh People's Hospital of Chengdu Chengdu 610041, Sichuan, PR China. 4. Department of Respiratory Medicine, West China Hospital, Sichuan University Chengdu 610041, Sichuan, PR China. 5. Department of Pathophysiology, Sichuan North Medical College Nanchong 637100, Sichuan, PR China.
Abstract
BACKGROUND: Expression of estrogen receptor beta (ERβ) is a potentially interesting prognostic marker and therapeutic target in non-small cell lung cancer (NSCLC). Although the expression of ERβ has been reported to correlate with better prognosis of NSCLC in most literatures, some controversies still exist. Since the limited patient numbers within independent studies, here we performed a meta-analysis to clarify the correlations between ERβ expression and prognosis in NSCLC. MATERIALS AND METHODS: We performed a final analysis of 2279 patients from 14 evaluable studies for Prognostic Value of overexpression ERβ (up to October 2014). Data from eligible studies were extracted and included into meta-analysis using a random effects model. Studies were pooled. Summary hazard ratios (HR) were calculated. RESULTS: Our study shows that the pooled hazard ratio (HR) of overexpression ERβ for overall survival in NSCLC was 0.78 [95% confidence interval (CI): 0.62-0.98] by univariate analysis and 1.06 (95% CI: 0.70-1.61) by multivariate analysis. Pooled HR in American and Japan was 1.09 (95% CI: 0.95-1.25, P=0.239) from 6 studies reported, however, pooled HR was 0.57 (95% CI: 0.46-0.70) outside of American and Japan from 8 studies reported. Pooled HR was 0.75 (95% CI: 0.60-0.94) from 6 studies reported for N-ERβ and 0.76 (95% CI: 0.51-1.12) from 6 Studies reported for C-ERβ. CONCLUSION: Our results suggested ERβ was significant associated with good overall survival in patients with NSCLC on univariate analysis but not multivariate analysis. ERβ expression is a good prognostic outcome outside of American and Japan. Overexpression of N-ERβ NSCLC patients had better survival. Large prospective studies are now needed to confirm the clinical utility of ERβ as an independent prognostic marker.
BACKGROUND: Expression of estrogen receptor beta (ERβ) is a potentially interesting prognostic marker and therapeutic target in non-small cell lung cancer (NSCLC). Although the expression of ERβ has been reported to correlate with better prognosis of NSCLC in most literatures, some controversies still exist. Since the limited patient numbers within independent studies, here we performed a meta-analysis to clarify the correlations between ERβ expression and prognosis in NSCLC. MATERIALS AND METHODS: We performed a final analysis of 2279 patients from 14 evaluable studies for Prognostic Value of overexpression ERβ (up to October 2014). Data from eligible studies were extracted and included into meta-analysis using a random effects model. Studies were pooled. Summary hazard ratios (HR) were calculated. RESULTS: Our study shows that the pooled hazard ratio (HR) of overexpression ERβ for overall survival in NSCLC was 0.78 [95% confidence interval (CI): 0.62-0.98] by univariate analysis and 1.06 (95% CI: 0.70-1.61) by multivariate analysis. Pooled HR in American and Japan was 1.09 (95% CI: 0.95-1.25, P=0.239) from 6 studies reported, however, pooled HR was 0.57 (95% CI: 0.46-0.70) outside of American and Japan from 8 studies reported. Pooled HR was 0.75 (95% CI: 0.60-0.94) from 6 studies reported for N-ERβ and 0.76 (95% CI: 0.51-1.12) from 6 Studies reported for C-ERβ. CONCLUSION: Our results suggested ERβ was significant associated with good overall survival in patients with NSCLC on univariate analysis but not multivariate analysis. ERβ expression is a good prognostic outcome outside of American and Japan. Overexpression of N-ERβ NSCLCpatients had better survival. Large prospective studies are now needed to confirm the clinical utility of ERβ as an independent prognostic marker.
Authors: Nadiyah Kazmi; Diana C Márquez-Garbán; Lilia Aivazyan; Nalo Hamilton; Edward B Garon; Lee Goodglick; Richard J Pietras Journal: Lung Cancer Manag Date: 2012-12
Authors: Ann G Schwartz; Geoffrey M Prysak; Valerie Murphy; Fulvio Lonardo; Harvey Pass; Jan Schwartz; Sam Brooks Journal: Clin Cancer Res Date: 2005-10-15 Impact factor: 12.531
Authors: Vianey Rodriguez-Lara; Erika Peña-Mirabal; Renata Baez-Saldaña; Ana Luisa Esparza-Silva; Eduardo García-Zepeda; Marco Antonio Cerbon Cervantes; Daniel Diaz; Teresa Imelda Fortoul Journal: Arch Med Res Date: 2014-01-28 Impact factor: 2.235
Authors: Adam W Nelson; Arnoud J Groen; Jodi L Miller; Anne Y Warren; Kelly A Holmes; Gerard A Tarulli; Wayne D Tilley; Benita S Katzenellenbogen; John R Hawse; Vincent J Gnanapragasam; Jason S Carroll Journal: Mol Cell Endocrinol Date: 2016-11-23 Impact factor: 4.102
Authors: Úna C McMenamin; James Trainor; Helen G Coleman; Damian T McManus; Stephen McQuaid; Victoria Bingham; Jacqueline James; Manuel Salto-Tellez; Brian T Johnston; Richard C Turkington Journal: Oncotarget Date: 2018-10-19